Lacosamide: new adjunctive treatment option for partial-onset seizures

Bibliography

• Centers for Disease Control and Prevention. Prevalence of self-reported epilepsy–United States, 1986 – 1990. JAMA 1994;272(24):1893
   PubMed Web of Science ®Google Scholar
• Chung S, Wang N, Hank N. Comparative retention rates and long-term tolerability of new antiepileptic drugs. Seizure 2007;16:296-304
   PubMed Web of Science ®Google Scholar
• Kwan P, Brodie M. Early identification of refractory epilepsy. N Engl J Med 2000;342:314-19
   PubMed Web of Science ®Google Scholar
• Perucca E. Development of new antiepileptic drugs: challenges, incentives, and recent advances. Lancet Neurol 2007;6:793-804
   PubMed Web of Science ®Google Scholar
• Andurkar SV, Stables JP, Kohn H. The anticonvulsant activities of N-benzyl 3-methoxypropionamides. Bioorg Med Chem 1999;7:2381-9
   PubMed Web of Science ®Google Scholar
• Hovinga CA. SPM-927 (Schwarz Pharma). IDrugs 2003;6:479-85
   PubMed Web of Science ®Google Scholar
• Beyreuther BK, Freitag J, Heers C, Lacosamide: a review of preclinical properties. CNS Drug Rev 2007;13:21-42
   PubMedGoogle Scholar
• Stöhr T, Kupferberg HJ, Stables JP, Lacosamide, a novel anti-convulsant drug, shows efficacy with a wide safety margin in rodent models for epilepsy. Epilepsy Res 2007;74:147-54
   PubMed Web of Science ®Google Scholar
• Brandt C, Heile A, Potschka H, Effects of the novel antiepileptic drug lacosamide on the development of amygdala kindling in rats. Epilepsia 2006;47:1803-9
   PubMed Web of Science ®Google Scholar
• Errington AC, Stöhr T, Heers C, Lees G. The investigational anticonvulsant lacosamide selectively enhances slow inactivation of voltage-gated sodium channels. Mol Pharmacol 2006;3:157-69
   Google Scholar
• Horstmann R, Bonn R, Cawello W, Basic clinical pharmacological investigations of the new antiepileptic drug SPM 927 [abstract]. Epilepsia 2002;43:188
   Google Scholar
• Cawello W, Kropeit D, Schiltmeyer B, Food does not affect the pharmacokinetics of SPM 927 [abstract]. Epilepsia 2004;45:307
   Web of Science ®Google Scholar
• Doty P, Rudd GD, Stoehr T, Thomas D. Lacosamide. Neurotherapeutics 2007;4:145-18
   PubMed Web of Science ®Google Scholar
• Thomas D, Scharfenecker U, Nickel B, Low potential for drug–drug interaction of lacosamide [abstract]. Epilepsia 2006;47:200
   Web of Science ®Google Scholar
• Bialer M, Johannessen SI, Kupferberg HJ, Progress report on the new antiepileptic drugs: a summary of the eigth eilat conference (EILAT VIII). Epilepsy Res 2007;73:1-52
   PubMed Web of Science ®Google Scholar
• Ben-Menachem E. Lacosamide: an investigational drug for adjunctive treatment of partial-onset seizures. Drugs Today 2008;44:35-40
   PubMed Web of Science ®Google Scholar
• U.S. Food and Drug Administration. Vimpat (lacosamide) tablets and injection: US prescribing information. Available from: http://www.fda.gov/cder/foi/label/2008/022253lbl.pdf. [Last accessed 30 October 2008]
   Google Scholar
• European Medicines Agency. Lacosamide (Vimpat): summary of product characteristics. Available from: http://www.emea.europa.eu/humandocs/PDFs/EPAR/vimpat/H-863-PI-en.pdf. [Last accessed 5 November 2008]
   Google Scholar
• Beydoun A, D'souza J, Hebert D, Doty P. Lacosamide: pharmacology, mechanisms of action and pooled efficacy and safety data in partial-onset seizures. Expert Rev Neurother 2009;9:33-42
   PubMed Web of Science ®Google Scholar
• Kropeit D, Schiltmeyer B, Cawello W, Bioequivalence of short-time infusions compared to oral administration of SPM 927 [abstract]. Epilepsia 2004;45:123
   Web of Science ®Google Scholar
• Bialer M, Johannessen S, Levy R, Progress report on new antiepileptic drugs: a summary of the ninth Eilat Conference (EILAT IX). Epilepsy Res 2009;83:1-43
   PubMed Web of Science ®Google Scholar
• Ben-Menachem E, Biton V, Jatuzis D, Efficacy and safety of oral lacosamide as adjunctive therapy in adults with partial-onset seizures. Epilepsia 2007;48:1308-17
   PubMed Web of Science ®Google Scholar
• Halász P, Kälviäinen R, Mazurkiewicz-Beldzinska M, Adjunctive lacosamide for partial-onset seizures: efficacy and safety results from a randomized controlled trial. Epilepsia 2009;50:443-53
   PubMed Web of Science ®Google Scholar
• Chung S, Sperling M, Biton V, Lacosamide: efficacy and safety as oral adjunctive treatment for partial-onset seizures. Epilepsia 2010. [Epub ahead of print]
   Google Scholar
• Wehner T, Bauer S, Hamer HM, Six months of postmarketing experience with adjunctive lacosamide in patients with pharmacoresistant focal epilepsy at a tertiary epilepsy center in Germany. Epilepsy Behav 2009;16:423-5
   PubMed Web of Science ®Google Scholar
• Rosenfeld W, Fountaine N, Kaubrys G, Lacosamide: an interim evaluation of long-term safety and efficacy as oral adjuctive therapy in subjects with partial-onset seizures [abstract]. Epilepsia 2007;48:318
   Web of Science ®Google Scholar
• Kennebäck G, Bergfeldt L, Tomson T. Electrophysiological evaluation of the sodium-channel blocker carbamazepine in healthy human subjects. Cardiovasc Drugs Ther 1995;9:709-14
   PubMed Web of Science ®Google Scholar
• Kennebäck G, Bergfeldt L, Vallin H, Electrophysiologic effects and clinical hazards of carbamazepine treatment for neurologic disorders in patients with abnormalities of the cardiac conduction system. Am Heart J 1991;121:1421-9
   PubMed Web of Science ®Google Scholar
• Matsuo F, Bergen D, Faught E, Placebo-controlled study of the efficacy and safety of lamotrigine in patients with partial seizures. US Lamotrigine Protocol 0.5 Clinical Trial Group. Neurology 1993;43:2284-91
   PubMed Web of Science ®Google Scholar
• Laville MA, de la Gastine B, Husson B, Should we care about pregabalin for elderly patients with a history of cardiac dysrhythmia? Rev Med Interne 2008;29:152-4
   PubMed Web of Science ®Google Scholar
• Biton V, Rosenfeld WE, Whitesides J, Intravenous lacosamide as replacement for oral lacosamide in patients with partial-onset seizures. Epilepsia 2008;49:418-24
   PubMed Web of Science ®Google Scholar
• Krauss G, Ben Menachem E, Mameniskiene R, Lacosamide: safety and tolerability of adjunctive intravenous lacosamide as short-term replacement for oral lacosamide in subjects with partial-onset seizures during 30-, 15-, and 10-minute infusions. Eur J Neurol 2007;14:319-20
   Web of Science ®Google Scholar
• Kellinghaus C, Berning S, Besselmann M. Intravenous lacosamide as successful treatment for nonconvulsive status epilepticus after failure of first-line therapy. Epilepsy Behav 2009;14:429-31
   PubMed Web of Science ®Google Scholar
• Tilz C, Resch R, Hofer T, Eggers C. Successful treatment for refractory convulsive status epilepticus by parenteral lacosamide. Epilepsia 2010;51:316-17
   PubMed Web of Science ®Google Scholar